RBP1 and prostate adenocarcinoma: Our findings revealed that RBP1 exhibited significant overexpression in esophageal carcinoma (ESCA), glioblastoma (GBM), head and neck squamous cell carcinoma (HNSC), and lung squamous cell carcinoma (LUSC), while showing marked decreases in bladder urothelial carcinoma (BLCA), kidney renal clear cell carcinoma (KIRC), kidney chromophobe (KICH), liver hepatocellular carcinoma (LIHC), kidney renal papillary cell carcinoma (KIRP), lung adenocarcinoma (LUAD), stomach adenocarcinoma (STAD), and prostate adenocarcinoma (PRAD) (Figure 1A).